• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 5. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Research Brief on N-Ethyl-2-fluoro-5-nitrobenzamide (CAS: 682757-54-6): Recent Advances and Applications

N-Ethyl-2-fluoro-5-nitrobenzamide (CAS: 682757-54-6) is a fluorinated nitrobenzamide derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This compound, characterized by its unique chemical structure featuring an ethyl group, a fluorine atom, and a nitro group, has been the subject of various studies exploring its synthetic pathways, biological activities, and potential therapeutic uses. The presence of the fluorine atom, in particular, enhances its metabolic stability and bioavailability, making it a promising candidate for further investigation.

Recent research has focused on the synthesis and optimization of N-Ethyl-2-fluoro-5-nitrobenzamide, with several studies reporting improved methodologies for its production. A 2023 study published in the Journal of Medicinal Chemistry detailed a novel catalytic approach that significantly increased the yield and purity of the compound, reducing the formation of by-products. This advancement is critical for scaling up production and ensuring consistent quality for further pharmacological evaluations. Additionally, computational studies have provided insights into the compound's molecular interactions, highlighting its potential as a scaffold for designing new bioactive molecules.

The biological activity of N-Ethyl-2-fluoro-5-nitrobenzamide has also been a focal point of recent investigations. Preliminary in vitro studies have demonstrated its efficacy as an inhibitor of certain enzymes involved in inflammatory pathways, suggesting potential applications in treating chronic inflammatory diseases. Moreover, its fluorinated structure has been shown to enhance its penetration through cell membranes, a desirable property for drug candidates targeting intracellular processes. These findings underscore the compound's versatility and its potential to serve as a lead compound in the development of novel therapeutics.

In addition to its therapeutic potential, N-Ethyl-2-fluoro-5-nitrobenzamide has been explored for its utility in chemical biology and proteomics. A 2024 study highlighted its use as a chemical probe to investigate protein-ligand interactions, leveraging its fluorescent properties to track binding events in real-time. This application opens new avenues for understanding complex biological systems and could facilitate the discovery of new drug targets. The compound's ability to selectively modify proteins also positions it as a valuable tool for studying post-translational modifications and their roles in disease mechanisms.

Despite these promising developments, challenges remain in the clinical translation of N-Ethyl-2-fluoro-5-nitrobenzamide. Issues such as pharmacokinetics, toxicity, and formulation stability need to be addressed through comprehensive preclinical studies. Recent efforts have begun to tackle these hurdles, with researchers employing advanced in silico modeling and high-throughput screening to optimize the compound's properties. Collaborative initiatives between academic institutions and pharmaceutical companies are also underway to accelerate its development and bring it closer to clinical trials.

In conclusion, N-Ethyl-2-fluoro-5-nitrobenzamide (CAS: 682757-54-6) represents a compelling area of research in the field of chemical biology and medicinal chemistry. Its unique structural features, combined with its diverse biological activities, make it a promising candidate for further exploration. Ongoing studies are expected to shed more light on its mechanisms of action and therapeutic potential, paving the way for its eventual application in treating various diseases. As research progresses, this compound may emerge as a key player in the development of next-generation pharmaceuticals.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)